Gilead weekly recap: Yeztugo PrEP retention, lenacapavir access, anito-cel progress

Gilead said Yeztugo exceeded expectations with strong retention as it expands PrEP options, secured regional access for lenacapavir and added six manufacturers to scale complex injectables. The company also said its anti-BCMA anito-cel is progressing toward bigger myeloma markets.